Title: Director, Research Manager

Company: AusPhage

Location: Rasmussen, QLD

Dr. Lisa Elliott is a consultant researcher located in Townsville Australia, with extensive skills and knowledge in aquaculture, microbiology, immunology, serology and phageology. Over the past 6 years, Dr. Elliott has been responsible for a diversity of projects including the successful development and application of bacteriophage preparations to control disease outbreaks such as Aeromonas hydrophila in aquaculture and Pseudomonas aeruginosa and Staphylococcus aureus in mammals. Since 2008, she has been in charge of the research, development and project management of bacteriophage projects as applied to therapeutic development, and the management of research teams. Today Dr. Elliott is the Director of AusPhage and manages and supports research projects for a variety of clients globally with a focus of multi drug resistant bacteria. In five years, Dr. Elliott intends to bring products into the market.

Previously, Dr. Elliott worked for Biologix as a senior research manager overseeing the research team and lab work, which provides valuable data to companies, industries, universities and governments. Now that she has her own practice, she provides the same services and products to Biologix as an independent consultant. She continues to work helping all types of companies, all industries, universities and governments through her practice as well. Dr. Elliott also acts as a guest speaker at conventions providing knowledge relating to her expertise in bacteriophage. Her work in the Aboriginal community addresses diseases like diabetes and many other illnesses.

AusPhage Pty Ltd was founded to address growing concern about the rise in antimicrobial resistance in bacteria.   A variety of antimicrobial and chemical treatments have been used to control and treat bacterial disease in humans, animals and production systems for many years. However, the World Health Organization report on global surveillance of antimicrobial resistance states, ‘Existing antimicrobials are losing their effect. At the same time there is a decline in the development of new antimicrobials. Similarly, there is insufficient new research into new diagnostics to detect resistant microorganisms, and vaccines for preventing and controlling infections. If this trend continues, the arsenals of tools to combat resistant microorganisms will soon be depleted.’ (WHO, 2014). AusPhage Pty Ltd specializes in the development of bacteriophage preparations effective at controlling pathogenic and problem bacteria naturally.